T he inflammatory response is a protective reaction to all acute and chronic infection. However, chronic or aberrant inflammatory response is considered a key pathological event in cardiovascular diseases, including endotoxic shock, hypertension, and coronary heart disease. 1 Nuclear factor κ B (NF-κB) is a key transcription factor and is essential to the initiation and development of inflammatory response. In mammals, the NF-κB family consists of 5 members, RelA/ p65, RelB, c-Rel, p50 (NF-κB1), and p52 (NF-κB2). Under normal conditions, the NF-κB dimers are maintained in inactive form in the cytoplasm in a complex with inhibitor of κB (IκB). After phosphorylation, IκB undergoes ubiquitination and degradation by the proteasome. IκB-free NF-κB dimers translocate into the nucleus and regulate the transcription of downstream genes. [2] [3] [4] Among genes regulated by NF-κB, cyclooxygenase (COX)-2, inducible nitric oxide synthase (iNOS), and cell adhesion molecules, including vascular cell adhesion molecule (VCAM)-1 and intercellular adhesion molecule (ICAM)-1, are well known and play significant roles in endothelial cell activation and dysfunction. [5] [6] [7] Thromboxane A 2 (TXA 2 ) is an eicosanoid produced by thromboxane synthase. Local and systemic elevations in TXA 2 have been reported in several thrombotic and vascular diseases. 8 TXA 2 binds the tTXA 2 receptor (TPr), a G proteinlinked receptor, which occurs as 2 alternatively spliced subtypes, TPα and TPβ, in humans. [9] [10] [11] TPr is expressed in a number of tissues, including platelets, placenta, vascular endothelial cells, and vascular smooth muscle cells.
TXA 2 can also attenuate endothelial insulin signaling through the rho-associated kinase (ROCK)/liver kinase B (LKB)1/ phosphatase and tensin homolog pathway. 18 TPr has also been reported to increase the expression of ICAM-1 and VCAM-1 in human endothelial cells through induction of NF-κB activation. 6, 19 However, how TPr activates NF-κB remains poorly understood. In this study, we investigated the mechanism underlying TPr activation of NF-κB in vascular cells. Our results demonstrate that LKB1 is required for TPrdependent NF-κB activation.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

U46619 and I-BOP Induce Expression of COX-2 in HUVECs
COX-2 plays a key role in the process of inflammation. 20, 21 To determine whether TPr agonists alter COX-2 expression, human umbilical vein endothelial cells (HUVECs) were starved overnight and treated with TPr agonist U46619 (1 μmol/L) 13, 22 for different periods of time. COX-2 expression was significantly increased 1 hour after U46619 treatment; expression peaked at 4 hours and decreased slightly after prolonged (>4 hours) incubation ( Figure 1A and 1B). U46619-induced COX-2 expression was also dose-dependent. Figure  1C and 1D show dose-dependent increase in COX-2 expression 4 hours after U46619 treatment, with a significant increase seen after treatment with 1 μmol/L U46619. Similarly, I-BOP, a TPr agonist that is structurally related to U46619, increased COX-2 expression in HUVECs in a time-dependent and dosedependent manner (data not shown).
Inflammatory proteins such as cell adhesion molecules and iNOS are well-characterized markers of NF-κB activation and play an important role in inflammation in endothelial cells. [23] [24] [25] To elucidate the important roles of TPr in vascular inflammation, we examined the effects of the TPr agonists, U46619 and I-BOP, on levels of ICAM-1, VCAM-1, and iNOS mRNA and protein in endothelial cells. Treatment of HUVECs with either U46619 or I-BOP for 4 hours enhanced expression of all 3 proteins ( Figure  1E ). Quantitative real-time polymerase chain reaction analysis consistently showed significant upregulation of ICAM-1, VCAM-1, iNOS, and COX-2 mRNAs by U46619 or I-BOP ( Figure 1F ).
U46619-and I-BOP-Enhanced Inflammation Is TPr Mediated
We next investigated whether TPr was required for U46619-triggered or I-BOP-triggered inflammatory responses. To this end, the TPr-specific antagonist, SQ29548 (10 μmol/L), 13 was added to HUVECs 30 minutes before the addition of U46619 or I-BOP. Whereas SQ29548 alone had no effect on basal levels of COX-2, iNOS, ICAM-1, and VCAM-1, SQ29548 reduced the levels of inflammatory protein ( Figure I in the online-only Data Supplement), and mRNA enhanced by U46619 ( Figure IB -ID in the online-only Data Supplement) and I-BOP (data not shown). These data provide strong evidence that TPr activation promotes inflammatory response in HUVECs. Because the effects of I-BOP and U46619 on TPr-enhanced expression of proinflammatory genes were highly comparable, we examined the effects of TPr activation by interchangeably using I-BOP or U46619. 26-28 Thus, we investigated whether TPr alters the phosphorylation of IκBα. I-BOP (1 μmol/L) increased the phosphorylation of IκBα in a time-dependent manner ( Figure 2A) , with a significant increase seen after 30 minutes of treatment ( Figure 2B ). I-BOP consistently lowered levels of total IκBα (Figure 2A ), suggesting that IκBα was degraded after being phosphorylated. [26] [27] [28] Similarly, I-BOP increased levels of p-IκBα in a dose-dependent manner ( Figure 2C) , with significant changes observed 30 minutes after treatment with a dose of at least 0.01 μmol/L I-BOP ( Figure 2D ).
TPr Activation Activates the NF-κB Pathway
TPr Activation of NF-κB Is TPr Dependent
To further confirm the effect of TPr activation on NF-κB activation, HUVECs were treated with SQ29548 (10 μmol/L), a TPr-specific antagonist, 30 minutes before treatment with TPr agonist (I-BOP). As expected, SQ29548 alone had no effect on phosphorylation of IκBα; however, the antagonist abolished the increase in p-IκB induced by TPr agonists ( Figure 2E and 2F).
TPr Activation Increases the Expression of Inflammatory Genes via NF-κB
IκB kinase (IKK)α/β are well-known upstream kinases of IκB phosphorylation. Phosphorylation of these kinases at Ser 177 and Ser 181 is linked to their activation. 4 Thus, we reasoned that TPr stimulation with I-BOP might activate NF-κB by phosphorylating IKK. I-BOP increased levels of p-IKKβ in a dosedependent and time-dependent manner ( Figure 3A and 3B).
To further explore whether the gene expression mediated by TPr agonists was NF-κB mediated, HUVECs were pretreated with NF-κB-specific inhibitor for 30 minutes before the addition of U46619 or I-BOP. Although the inhibitor alone had no effect, it significantly attenuated TPr-enhanced inflammatory gene expression in HUVECs ( Figure 3C ).
Translocation of NF-κB subunit p65 into nuclei is a pivotal step in NF-κB activation. Thus, p65-specific small interfering RNA (siRNA) was used to suppress the activity of NF-κB. p65 was significantly decreased by p65-specific siRNA, compared with control siRNA ( Figure 3D ). As expected, TPr agonist treatment increased the expression of iNOS, COX-2, VCAM-1, and ICAM-1 in cells treated with control siRNA, but not in those treated with p65 siRNA, indicating that NF-κB activation is required for TPr upregulation of COX-2, VCAM-1, ICAM-1, and iNOS expression in endothelial cells.
LKB1 Phosphorylation Is Required for TPr-Induced NF-κB Activation
We previously reported that TPr stimulation increases the phosphorylation of LKB1 at serines 428 and 307 13 in vascular smooth muscle cells. 18 Thus, we investigated whether TPr stimulation alters the phosphorylation of LKB1 at Ser 428 in HUVECs. U46619 increased the level of p-LKB1 in these cells in a time-dependent manner ( Figure 4A at 120 minutes, after U46619 treatment. I-BOP also increased the phosphorylation of LKB1 in HUVECs (data not shown). Next, we assayed whether genetic suppression of LKB1 alters TPr-induced NF-κB activation. As expected, transfection of LKB1-specific siRNA did not affect basal levels of p-IκB; however, LKB1-specific siRNA, but not control siRNA, significantly abolished I-BOP-induced or U46619-induced increase in p-IκB ( Figure 4B and 4C). Consistently, LKB1 siRNA, but not control siRNA, attenuated I-BOP-enhanced or U46619-enhanced IKKβ phosphorylation ( Figure 4D ). Finally, LKB1 siRNA, but not control siRNA, abolished the overexpression of VCAM-1, ICAM-1, and iNOS ( Figure 4E ). Taken together, these results indicate that LKB1 phosphorylation by TPr is required for the expression of inflammatory genes in HUVECs.
To further confirm the role of LKB1 in TPr-induced NF-κB activation, we tested whether overexpression of an LKB1 phosphorylation-defective mutant (LKB1-S428A, in which serine 428 is replaced with alanine) altered TPr-induced phosphorylation of IKK and consequent NF-κB activation. Because endothelial cells are difficult to transfect with plasmids, we performed the experiments using a human monocytic cell line, THP-1, which is deficient in LKB1. As shown in Figure 4F , THP-1 cells expressed no detectable LKB1. Compared with THP-1 cells transfected with LacZ, THP-1 cells overexpressing wild-type LKB1 showed increased phosphorylation of IKKβ, p65, and IκB. In contrast, overexpression of mutants LKB1-S428A or LKB1-D194A (in which Asp 194 is replaced with alanine), or of plasmids encoding AMP-activated protein kinase (AMPK)α1 or AMPKα2, had no effect on the phosphorylation of IKK, p65, or IκB ( Figure 4F ). Taken together, these results suggest that overexpression of LKB1, but not AMPKα1 or AMPKα2, increases NF-κB activation in THP-1 cells.
As expected, U46619 markedly increased the level of phosphorylated forms of IKK, p65, and IκB in THP-1 cells transfected with wild-type LKB1 ( Figure 4F ). Interestingly, U49919-enhanced phosphorylation of IKK, p65, and IκB was absent in cells overexpressing LKB1 mutants or AMPK ( Figure 4F ). Taken together, these results further confirm that TPr, via LKB1 phosphorylation at Ser 428, is required for AMPK-independent NF-κB activation.
Antioxidants Do Not Affect TPr-Induced NF-κB Activation
We had previously reported that TPr increased reactive oxygen species (ROS) in both endothelial cells and vascular smooth muscle cells. 13, 29 As expected, incubation of U46619 significantly increased ROS production in HUVECs (data not shown). To establish whether ROS was involved in TPrenhanced NF-κB-mediated COX-2 expression, HUVECs were preincubated with tempol or mitotempol, 2 potent antioxidants, before the addition of U46619 or I-BOP. As depicted in Figure IIA in the online-only Data Supplement, tempol or mitotempol, which alone slightly increased COX-2 expression, caused a further enhancement of COX-2 in I-BOPtreated HUVECs. Consistently, tempol or mitotempol could not change the increase of p-IκBα mediated by I-BOP ( Figure  IIB in the online-only Data Supplement), indicating that ROS was not required for TPr-increased NF-κB activation.
Silencing of Atypical Protein Kinase C-ζ Does Not Alter TPr-Induced NF-κB Activation
Atypical protein kinase C-ζ (PKC-ζ) is reported to be responsible for LKB1-dependent AMPK activation. 30, 31 To 
Chelation of Exogenous Calcium With EDTA Abolishes TPr Agonist-Induced NF-κB Activation
Increase of intracellular calcium is a central event in TPr signaling. 32 Thus, it was important to investigate whether calcium chelation inhibited TPr-induced NF-κB activation. As depicted in Figure IID in the online-only Data Supplement, EDTA, a calcium chelator, abolished the phosphorylation of IκB, indicating that TPr-induced calcium increase was required for NF-κB activation in endothelial cells.
ROCK Is the Upstream Regulator of LKB1
Because the results described above refuted the involvement of ROS/PKCζ in TPr-induced NF-KB activation and we had previously found that TPr alters ROCK activity, 18 we reasoned that ROCK might be important for LKB1 phosphorylation and consequent induction of inflammatory genes in HUVECs. As shown in Figure 5A , U46619 activated Rho protein in a TPr-dependent manner. As expected, Rho/ROCK inhibitor Y27632 abolished U46619-enhanced phosphorylation of LKB1 ( Figure 5B ), suggesting that ROCK might be an upstream regulator of LKB1. We next investigated whether Y27632 alters TPr-induced NF-KB activation in HUVECs. Y27632 totally blocked the increase in phosphorylation of IκBα and the decrease in total IκBα induced by U46619 ( Figure 5C and 5D) , which suggests that the Rho/ ROCK pathway is the upstream regulator of NF-κB. 
Inhibition of ROCK Blocks TPr-Enhanced Vascular Inflammation
To determine whether ROCK/LKB1 serves as an intermediate component of the TXA 2 -TPr signaling pathway regulating the inflammatory response, a specific inhibitor of ROCK, Y27632, was added to HUVECs before the addition of TPr agonists. Y27632 ablated TPr-enhanced expression of ICAM-1, VCAM-1, iNOS, and COX-2 ( Figure 5E ). Downregulation of ICAM-1, VCAM-1, and COX-2 by Y27632 was further confirmed by real-time polymerase chain reaction ( Figure 5F ).
TPr Activation Impairs Cell Migration and Increased THP-1 Adhesion Through NF-κB Activation
We next investigated whether TPr agonists affect endothelial cell migration in a Boyden chamber assay. The TPr agonist U46619 significantly impaired cell migration ( Figure IIIA in the online-only Data Supplement). To further confirm whether this impairment is attributable to TPr-enhanced NF-κB activation, HUVECs were pretreated with SQ29548, Y27632, or NF-κB activation inhibitor before treatment with U46619. SQ29548, Y27632, or NF-κB activation inhibitor alone abolished U46619-impaired migration ( Figure IIIA in the online-only Data Supplement), suggesting that NF-κB activation by ROCK is required for U46619 impairment of endothelial cell migration.
Next, we investigated the effects of TPr agonists on cell adhesion. HUVECs were treated with U46619 overnight and incubated with stained THP-1 cells for 30 minutes. Adhesion of THP-1 cells increased in U46619-stimulated HUVECs, and U46619-enhanced adhesion was blocked in cells pretreated with SQ29548, Y27632, or NF-κB inhibitor ( Figure IIIB in the online-only Data Supplement). Taken together, these results support the essential role of ROCK-mediated NF-κB activation in endothelial adhesion activity.
TPr Activation Triggered Inflammatory Response in Mice Through NF-κB Activation
Finally, we determined whether TPr agonists triggered a whole-body inflammatory response via NF-κB activation. C57BL/6 mice that had been pretreated with NF-κB inhibitor or vehicle alone were administered U46619. Serum was collected, and cytokines were determined. U46619 significantly increased the levels of interleukin-1β, interleukin-6, and necrosis factorα ( Figure IV in the online-only Data Supplement). Importantly, pretreatment with NF-κB inhibitor ablated U46619-induced elevation of the cytokines, compared with pretreatment with vehicle alone.
TPr-Induced NF-κB Activation Impaired Endothelium-Dependent Relaxation
We thought it would be interesting to determine whether TPr-induced NF-κB-mediated expression of the inflammatory genes ICAM-1, VCAM-1, and COX-2 occurs in intact vascular explants and whether overexpression of inflammatory molecules impairs endothelium-dependent relaxation after U46619 treatment. To this end, mouse aortic rings were prepared and assayed for inflammatory markers and acetylcholine-induced endothelium-dependent relaxation. U46619 markedly increased the levels of VCAM-1 and COX-2 and, importantly, pretreatment with NF-κB inhibitor abolished the U46619-induced overexpression ( Figure 6A ).
We next investigated whether U46619-enhanced NF-κB activation results in abnormal endothelium-dependent relaxation. U46619 caused a 30% reduction in endothelium-dependent vasorelaxation compared with vehicle-treated aortic rings ( Figure 6B ). U46619 treatment had no effect on endotheliumindependent relaxation (data not shown). Unlike U46619, exposure of vessels to phenylephrine, a selective α1-adrenergic receptor agonist, did not alter acetylcholine-induced vasorelaxation (data not shown). Furthermore, pretreatment with SQ29548 or NF-κB inhibitor abolished U46619-impaired vasorelaxation ( Figure 6B ), suggesting that TPr-mediated NF-κB activation is responsible for impaired relaxation.
Because TPr agonists markedly increased the expression of COX-2, we investigated whether inhibition of COX-2 by NS398, a selective COX-2 inhibitor, has an effect on endothelium-dependent relaxation. As expected, the addition of NS398 significantly improved acetylcholine-induced vasorelaxation ( Figure 6C ), suggesting that COX-2-derived factors might contribute to impaired endothelium-dependent vasorelaxation in intact vessels.
Discussion
Increasing evidence indicates that aberrant activation of TPr contributes to the initiation and progression of cardiovascular diseases, including atherosclerosis, hypertension, and diabetes mellitus. The present study has unveiled a novel mechanism, whereby TPr, via ROCK-mediated LKB1-dependent NF-κB activation, triggers aberrant vascular inflammation accompanied by impaired vasorelaxation in vivo. Consistently, inhibition of ROCK or LKB1 blocked TPr agonist-mediated NF-κB activation. Finally, inhibition of COX-2, a well-characterized downstream effector of NF-κB, normalized endotheliumdependent relaxation. Overall, our results suggest that ROCKmediated, but LKB1-dependent, NF-κB activation by TPr might be responsible for aberrant inflammation and vascular dysfunction often seen in cardiovascular diseases ( Figure 6D) .
The most important finding of this study is the identification of LKB1-dependent NF-κB activation and consequent inflammation in vascular endothelial cells. Overexpression of LKB1, but not AMPK, increased the phosphorylation of IKK and IKBα with the expression of NF-κB effector genes, including ICAM-1, iNOS, and COX-2. Consequently, LKB1 knockdown decreased the phosphorylation of IKKβ mediated by TPr agonists. Interestingly, the effects of LKB1 on NF-κB activation seem to be dependent on ROCK-induced LKB1 phosphorylation. First, we found that ROS-activated PKC-ζ pathway, which is important in LKB1-dependent AMPK activation, was not involved in TPr-induced NF-κB activation, suggesting that neither PKC-ζ nor AMPK are required; Second, inhibition of ROCK with Y27632 blocked TPr-induced NF-κB activation and induction of NF-κB target genes. Finally, the most conclusive evidence, supporting an essential role of LKB1 phosphorylation in TPr-induced NF-κB activation, is that overexpression of a phosphorylationdefective LKB1 mutant (LKB1-S428A) blocked NF-κB activation. Indeed, we previously reported that TPr agonists increase LKB1 phosphorylation at Ser 428, and that TPractivated, Rho-mediated LKB1 phosphorylation attenuates insulin signaling in endothelium. 18 Because inflammation is a known risk factor for insulin resistance, it is highly anticipated that NF-κB-mediated inflammation might be involved in TPrinduced insulin resistance.
LKB1-enhanced NF-κB activation seems to be mediated by increased IKK phosphorylation. Whether IKK is phosphorylated by LKB1 or another of the LKB1 family kinases remains unclear, and this warrants further investigation. AMPK is one of 14 downstream targets of LKB1, 33 and the role of AMPK in NF-κB signaling is highly controversial. For example, AMPK has been reported to directly phosphorylate IKKβ. 34 However, our published work and the work of others indicate that AMPK activation inhibited NF-κB activation in endothelial cells, and mice deficient in AMPKα2 exhibited excessive activation of NF-κB. 35 Although the roles of AMPK in the NF-κB pathway remain to be determined, our results suggest that LKB1-dependent IKK phosphorylation is independent of AMPK. Further investigation is warranted.
Endothelium can be considered as an initial pathogenic factor in many diseases, and endothelial cell activation and dysfunction impair cell function or cause vascular inflammation. 36, 37 Another important finding of this study is that aberrant NF-κB activation by TPr activation causes impairment of endothelium-dependent relaxation in vivo. We have further reported that selective inhibition of COX-2 normalizes vascular relaxation in aortic rings, supporting the idea that NF-κB-mediated induction of COX is operational in intact vascular explants. Importantly, small doses of TPr trigger whole-body inflammation, as evidenced by increased serum cytokine levels in mice in vivo. These results suggest that TPr induces systemic inflammation, and that TPrinduced inflammation extends beyond vascular walls. Thus, our results support the concept that overproduction of TPr is a potent inducer of both vascular and systemic inflammation. As a result, TPr antagonists, ROCK inhibitors, or inhibition of LKB1 are potential key targets to inhibit TXA 2 -induced inflammation in relevant diseases, such as diabetes mellitus, in which increased TXA 2 release is evident. 38 In conclusion, this study provides evidence that LKB1 is required for TPr-instigated systemic inflammation, and that inhibition of LKB1 or ROCK might be effective in preventing TPr-induced vascular dysfunction and related disorders.
Sources of Funding
This study was supported by funding from the following agencies: the National Institutes of Health RO1 (HL074399, HL079584, HL080499, HL08920, HL096032, HL105157, and HL110488), the American Diabetes Association, and the Warren Endowed Chair of TPr agonist induced inflammatory response in mice through NF-κB activation. Mice were pretreated with or without NF-κB inhibitor and treated with U46619 overnight, and levels of indicated serum cytokines were determined. Data are means ± SEM. (n=5-7; *, p<0.05 versus control; #, p<0.05 versus U46619 alone).
